Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy

L. Boglione; A. De Nicolò; C. S. Cardellino; T. Ruggiero; V. Ghisetti; G. Cariti; G. Di Perri; A. D'Avolio

doi:10.1016/j.cmi.2014.07.009

Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy

L. Boglione
, A. De Nicolò
, C. S. Cardellino
, T. Ruggiero
, V. Ghisetti
, G. Cariti
, G. Di Perri
, A. D'Avolio

Research output: Contribution to journal › Article › peer-review

Abstract

In a prospective cohort of 18 patients treated with boceprevir, we examined the role of boceprevir plasma concentration at the onset of breakthrough during the treatment. Nine patients experienced breakthrough during therapy. The resistance patterns were as follows: S122S/R, I132V, T54A/I132V, V156S/I170A, V36M/T54S/R155K, V36M/R155K and T54/R155K. Boceprevir-S isomer (SCH 534128) median concentration in patients with breakthrough was 48.3ng/mL (interquartile range 43-58ng/mL); in others, it was significantly (p 0.019) higher: 151ng/mL. Low boceprevir plasma concentration can lead to virologic resistance; therapeutic drug monitoring should be used to prevent the onset of viral breakthrough during triple-regimen therapy with boceprevir.

Original language	English
Pages (from-to)	205.e1-205.e3
Journal	Clinical Microbiology and Infection
Volume	21
Issue number	2
DOIs	https://doi.org/10.1016/j.cmi.2014.07.009
Publication status	Published - 1 Feb 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Boceprevir
Breakthrough
HCV
Resistance
Triple therapy

Access to Document

10.1016/j.cmi.2014.07.009

Cite this

@article{9e10b948e55547aabb1e4f6735636fc8,

title = "Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy",

abstract = "In a prospective cohort of 18 patients treated with boceprevir, we examined the role of boceprevir plasma concentration at the onset of breakthrough during the treatment. Nine patients experienced breakthrough during therapy. The resistance patterns were as follows: S122S/R, I132V, T54A/I132V, V156S/I170A, V36M/T54S/R155K, V36M/R155K and T54/R155K. Boceprevir-S isomer (SCH 534128) median concentration in patients with breakthrough was 48.3ng/mL (interquartile range 43-58ng/mL); in others, it was significantly (p 0.019) higher: 151ng/mL. Low boceprevir plasma concentration can lead to virologic resistance; therapeutic drug monitoring should be used to prevent the onset of viral breakthrough during triple-regimen therapy with boceprevir.",

keywords = "Boceprevir, Breakthrough, HCV, Resistance, Triple therapy",

author = "L. Boglione and \{De Nicol{\`o}\}, A. and Cardellino, \{C. S.\} and T. Ruggiero and V. Ghisetti and G. Cariti and \{Di Perri\}, G. and A. D'Avolio",

note = "Publisher Copyright: {\textcopyright} 2014 European Society of Clinical Microbiology and Infectious Diseases.",

year = "2015",

month = feb,

day = "1",

doi = "10.1016/j.cmi.2014.07.009",

language = "English",

volume = "21",

pages = "205.e1--205.e3",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy

AU - Boglione, L.

AU - De Nicolò, A.

AU - Cardellino, C. S.

AU - Ruggiero, T.

AU - Ghisetti, V.

AU - Cariti, G.

AU - Di Perri, G.

AU - D'Avolio, A.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - In a prospective cohort of 18 patients treated with boceprevir, we examined the role of boceprevir plasma concentration at the onset of breakthrough during the treatment. Nine patients experienced breakthrough during therapy. The resistance patterns were as follows: S122S/R, I132V, T54A/I132V, V156S/I170A, V36M/T54S/R155K, V36M/R155K and T54/R155K. Boceprevir-S isomer (SCH 534128) median concentration in patients with breakthrough was 48.3ng/mL (interquartile range 43-58ng/mL); in others, it was significantly (p 0.019) higher: 151ng/mL. Low boceprevir plasma concentration can lead to virologic resistance; therapeutic drug monitoring should be used to prevent the onset of viral breakthrough during triple-regimen therapy with boceprevir.

AB - In a prospective cohort of 18 patients treated with boceprevir, we examined the role of boceprevir plasma concentration at the onset of breakthrough during the treatment. Nine patients experienced breakthrough during therapy. The resistance patterns were as follows: S122S/R, I132V, T54A/I132V, V156S/I170A, V36M/T54S/R155K, V36M/R155K and T54/R155K. Boceprevir-S isomer (SCH 534128) median concentration in patients with breakthrough was 48.3ng/mL (interquartile range 43-58ng/mL); in others, it was significantly (p 0.019) higher: 151ng/mL. Low boceprevir plasma concentration can lead to virologic resistance; therapeutic drug monitoring should be used to prevent the onset of viral breakthrough during triple-regimen therapy with boceprevir.

KW - Boceprevir

KW - Breakthrough

KW - HCV

KW - Resistance

KW - Triple therapy

UR - https://www.scopus.com/pages/publications/84922981045

U2 - 10.1016/j.cmi.2014.07.009

DO - 10.1016/j.cmi.2014.07.009

M3 - Article

SN - 1198-743X

VL - 21

SP - 205.e1-205.e3

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

IS - 2

ER -

Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this